Persistent pulmonary hypertension of the newborn is characterized by elevated pulmonary vascular resistance after birth leading to right-to-left shunting and systemic arterial hypoxemia. Inhaled nitric oxide (NO) is effective in reducing the need for extracorporeal membrane oxygenation, but it has potential toxicities, especially in an oxygen-rich environment. A number of other NO-based molecules have been given by inhalation, but their structure-function relationships have not been established. Recent studies have raised the idea that toxic and beneficial properties can be separated. We synthesized a novel organic nitrate [ethyl nitrate (ENO 2 )], tested it in vitro, and administered it to hypoxic piglets. ENO 2 lowered pulmonary artery pressure and raised the PO 2 in arterial blood but did not alter systemic vascular resistance or methemoglobin levels. In addition, we tested the effect of ENO 2 in the presence of the thiol glutathione, both in vivo and in vitro, and found its action to be enhanced. Although ENO 2 is less potent than inhaled NO on a doseequivalency basis, pretreatment of hypoxic animals with glutathione, which may be depleted in injured lungs, led to a markedly enhanced effect (largely mitigating the difference in potency). The disease entity persistent pulmonary hypertension of the newborn (PPHN) is characterized by elevated pulmonary vascular resistance (PVR) after birth leading to extrapulmonary right-to-left shunting through the patent foramen ovale and patent ductus arteriosus with resulting systemic arterial hypoxemia. These patients are frequently treated with inhaled nitric oxide (NO) and may require extracorporeal membrane oxygenation; those with severe respiratory failure are at increased risk for neurodevelopmental impairment (1,2). NO's clinical effectiveness has been well documented (3-6), although some reports suggest that it may exacerbate lung inflammation (7), raising the concern that it may have toxic properties in some clinical settings. Infants who receive inhaled NO for PPHN are often treated with high inspired oxygen, and in the O 2 -rich environment of the lung, higher oxides of nitrogen (NO x ) including peroxynitrite may form (8), which can cause hemorrhage, inflammation, and edema (9,10). Airways of animal and human subjects who have received inhaled NO showed the same patterns of oxidative injury found in animals and humans who were exposed to NO x or hyperoxia (11, 12) .
The disease entity persistent pulmonary hypertension of the newborn (PPHN) is characterized by elevated pulmonary vascular resistance (PVR) after birth leading to extrapulmonary right-to-left shunting through the patent foramen ovale and patent ductus arteriosus with resulting systemic arterial hypoxemia. These patients are frequently treated with inhaled nitric oxide (NO) and may require extracorporeal membrane oxygenation; those with severe respiratory failure are at increased risk for neurodevelopmental impairment (1, 2) . NO's clinical effectiveness has been well documented (3) (4) (5) (6) , although some reports suggest that it may exacerbate lung inflammation (7) , raising the concern that it may have toxic properties in some clinical settings. Infants who receive inhaled NO for PPHN are often treated with high inspired oxygen, and in the O 2 -rich environment of the lung, higher oxides of nitrogen (NO x ) including peroxynitrite may form (8) , which can cause hemorrhage, inflammation, and edema (9, 10) . Airways of animal and human subjects who have received inhaled NO showed the same patterns of oxidative injury found in animals and humans who were exposed to NO x or hyperoxia (11, 12) .
Inhaled, exogenous NO is delivered to well-ventilated parts of the lung and will stimulate guanylate cyclase activity, leading to vascular smooth muscle relaxation. Thus, NO has been effective in lowering pulmonary artery pressure (PAP) and PVR without compromising left ventricular function or systemic arterial pressure. As a result, it has been effective in preventing progression to severe PPHN (3), reducing ventilatory support (3) , and lessening the need for extracorporeal membrane oxygenation (5) . However, in addition to questions about its toxicity, its clinical use has potential drawbacks, which may include methemoglobinemia (13) , impairment of left ventricular function (14) , impairment of platelet aggregation (15) , and "rebound" pulmonary hypertension (16) . NO is frequently difficult to administer, and the cost of its use may be staggering (17) .
We previously tested a novel inhaled drug, ethyl nitrite (ENO; O-nitrosoethanol), which mimicked NO synthase activity by forming S-nitrosothiols (SNOs) in vitro (18) . This drug was effective in mitigating hypoxia-induced pulmonary hypertension and showed promise in improving oxygenation in pulmonary hypertensive neonates (19) . ENO did cause, however, modest increases in methemoglobin concentration and a rise in blood ethanol level (in a single infant with liver injury). To better understand the structure-function relationship of this class of compounds, we synthesized a closely related derivative, ethyl nitrate (ENO 2 ; O-nitroethanol). We hypothesized that as a volatile organic nitrate, it might have an advantage over other vasodilators in that it could be converted easily into an inhaled form and thus selectively dilate the pulmonary vascular bed; in addition, although it would not fortify the body's SNO reservoir as markedly as ENO, its action might be enhanced by thiols such as glutathione, which may be depleted in lung injury (20) . We tested our synthetic compound in a vascular bioassay in vitro and in a hypoxic model of PPHN.
METHODS
Preparation of ethyl nitrate. ENO 2 was prepared by sulfuric acid-induced nitration of ethanol. Nitric acid (25 mL) was mixed slowly with sulfuric acid (25 mL). Urea (160 mg) was added. The solution was cooled in an ice water bath. Ethanol (15 mL) was added dropwise in portions over a period of 1 h. After complete addition, the solution was stirred for 10 min more. The mixture was added to a solution of cold (4°C) brine in a separation funnel. The bottom (aqueous) layer was discarded, and the top layer was washed twice with cold, saturated sodium bicarbonate (15 mL), resulting in the evolution of gas. The top layer was washed with cold brine (15 mL), dried with powdered magnesium sulfate, and filtered to give ENO 2 as a clear, colorless liquid. . Gas chromatography-mas spectrometry analysis (J&W Scientific GS-Q column, Folson, CA) of the head space of a vial of prepared ENO 2 showed the compound to be free of higher NO x : two peaks were observed, one of room air, the other with a mass spectrum consistent with ENO 2 . ENO 2 did not measurably decompose on exposure to air, water, propylene glycol, DMSO, methanol, or ethanol.
An ENO 2 gas admixture was generated by passing either 14 or 21% oxygen, at 0.6 L/min, through a small glass mixing column (URG, Chapel Hill, NC) filled with rasching rings and containing liquid ENO 2 in a propylene glycol solution. Concentrations of ENO 2 delivered by this system were changed by varying solution concentrations (0.0025, 0.025, 0.125, 1.25, and 2.5%). Experiments done with "control" gas used propylene glycol in the mixing column, without the addition of ENO 2 .
Pulmonary artery ring preparation. The ring procurement protocol was approved by the Duke University animal care and use committee. New Zealand White rabbits (2.5-3 kg) were killed by carbon dioxide inhalation. As vessels would be chemically constricted to mimic hypoxic constriction, vessels from mature rabbits were deemed sufficient. The pulmonary artery was removed and cleared of fat and connective tissue, and second-and third-order branches were cut into 3-mm rings. The rings were prepared and hung as previously described (22) . A total of eight pulmonary artery rings from two rabbits were used. Contractions were initiated with phenylephrine, and endothelial function was assessed by the response to 10 Ϫ7 mol/L acetylcholine; relaxation of Ͼ50% was considered adequate. Liquid ENO 2 was added to the baths at an initial concentration of 10 Ϫ9 mol/L and then increased 10-fold at a time to a final concentration of 10 Ϫ4 mol/L. Glutathione (GSH) was tested at up to 10
Surgical model of pulmonary hypertension. The protocol was approved by the Duke University animal care and use committee. A total of 21 neonatal swine (1-2 wk of age; 2.6 -4.0 kg) were anesthetized and instrumented as previously described (23) . Pressure monitors directly measured the pressure in the main pulmonary artery, right ventricle, and left atrium. A flow probe around the pulmonary artery continuously measured cardiac output (CO). In each of a subgroup of these animals (n ϭ 7), the ductus arteriosus was found to be patent by placement of a pressure catheter in the ductus during hypoxia, as well as by postmortem examination. Mechanical ventilation was initiated with a V.I.P. Bird ventilator (SensorMedics, Yorba Linda, CA) in volume control mode. Ketamine (22 mg/kg) and acepromazine (1.1 mg/kg) were given intramuscularly as preanesthetics. Anesthesia was maintained during the study with a continuous infusion of fentanyl (20 
), abating some of the inherent instability of the open-chest preparation, and intermittent doses of pancuronium (0.1 mg/kg) were given for neuromuscular blockade. Blood pressure and heart rate were monitored continuously. Before data acquisition, animals were allowed to stabilize for 20 min.
After instrumentation, lowering the fraction of inspired oxygen (FIO 2 ) to 0.14 induced pulmonary hypertension. By 7 min, the PAP had plateaued and the other parameters had reached a constant level. At this point, baseline measurements were taken; measurements were retaken after 5 min of breathing ENO 2 . The inhaled ENO 2 then was stopped, and the animals continued on the low FIO 2 for an additional 5 min, at which point hemodynamic measurements were obtained and the FIO 2 returned to 0.21. The procedure was repeated three times using different doses of ENO 2 in random order. For the experiments involving thiol supplementation, seven of the animals were pretreated with GSH (50 mg/kg, by i.v. infusion over 20 min) before induction of pulmonary hypertension (hypoxia); the procedure described above then was followed.
Ventilation and gas administration. Mechanical ventilation was used with an initial rate of 35 breaths/min and a tidal volume sufficient to return 7-9 mL/kg. Positive end expiratory pressure was set at 5 cm H 2 O, and flow was 6 L/min. FIO 2 was 0.21 before the start of all experiments. Blended air from the ventilator flow meter was directed into the glass mixing column at a flow rate of 0.6 L/min. The gas that came out of the mixing column (containing gaseous ENO2) was added via t-connector to the inspiratory tubing of the ventilator.
Inspired gas (400 L) was sampled by gastight syringe (Hamilton Co., Reno, NV) through a rubber septum on a port 100 mm proximal to the endotracheal tube. The minute quantities of ENO 2 gas to be analyzed were hydrolyzed with potassium hydroxide (KOH) to potassium nitrite (KNO 3 ), which were quantified, after vanadium chloride (VCL 3 ) reduction to NO, with a commercial NO (NOA) analyzer (Model 280 NO analyzer; Sievers Instruments, Boulder, CO), which was configured and run according to the manufacturer's instructions. ENO 2 was unexpectedly resistant to base-induced hydrolysis; solutions of authentic ENO 2 required 72 h at 95°C in 100 mM KOH in a 9:1 mixture of propylene glycol:water to yield 100% nitrate (KOH concentration was minimized to reduce background nitrate). The gas was injected into a 200-L solution of 100 mM KOH in 9:1 propylene glycol:water in a 2-mL screw-cap vial. The vial was immediately covered with a screw cap that contained an intact PTFE-faced septum and put on a heat block at 95°C for at least 72 h. After cooling, aliquots were removed and analyzed for nitrate content by the NOA. Molar quantities of ENO 2 were converted to parts per million (ppm) by application of the ideal gas law.
Data collection and analysis. In vivo data were collected via pressure catheters connected to a data acquisition system customized in our laboratory. Least squares means for the different interventional states were calculated using multiple linear regression, and tests of statistical significance were carried out using repeated measures ANOVA followed by paired t tests with Bonferroni correction. All data were expressed as mean Ϯ SE. In vitro data were analyzed using ANOVA with Tukey-Kramer honestly significant difference (JMP statistical software, Cary, NC). A p Ͻ 0.05 was considered statistically significant. Analyses were performed using SAS statistical software (SAS Institute, Inc., Cary, NC).
RESULTS

Dose-dependent response to ENO 2 in vitro.
Pulmonary artery rings that were exposed to ENO 2 showed no vasodilation 532 at concentrations below 10 Ϫ7 mol/L. Dose-dependent relaxation was seen between 10 Ϫ7 and 10 Ϫ4 mol/L with IC 50 ϭ 10 Ϫ4.5 mol/L (Fig. 1) . Addition of GSH (1 mM) resulted in a small increase in ENO 2 potency (p Ͻ 0.05 by multivariate analysis). Univariate analysis also showed a significant potentiation of ENO 2 relaxations in the presence of 10 Ϫ4 mol/L GSH (p Ͻ 0.05). An equivalent volume of ethanol, with and without GSH, produced no relaxation.
Induction of pulmonary hypertension. Table 1 shows the effect of lowering the FIO 2 to 0.14 for 7 min. This degree of hypoxia resulted in a 59% rise in PAP and a 49% increase in PVR (p Ͻ 0.05 for both). The arterial PO 2 (PaO 2 ) decreased by 52% (p Ͻ 0.01). The only statistically significant effect on systemic hemodynamics was a drop in mean arterial blood pressure by 16% (p Ͻ 0.05), although the characteristic decline in systemic vascular resistance (SVR) and compensatory increase in CO was observed. These results are similar to those found in other hypoxic models of pulmonary hypertension (18, 24) .
Effect of control gas on pulmonary hypertension. To test the effect of delivering air into the inspiratory limb of the ventilatory circuit at 0.6 L/min, we performed control experiments that consisted of filling the glass chamber with only propylene glycol (0% ENO 2 ) and then passing gas with an FIO 2 of 0.14 through it. In this set-up, the inspiratory and expiratory tidal volumes increased by 5-8%, but the minute ventilation increased by no more than 4%. None of changes in measured parameters reached statistical significance (p Ͻ 0.05, data not shown).
Effect of ENO 2 on pulmonary hypertension. Figure 2 shows the changes in several physiologic parameters after ENO 2 administration during hypoxia. There was both a significant decrease in PAP and an increase in PaO 2 at doses of 0.125, 1.25, and 2.5% ENO 2 (p Ͻ 0.05), with the last two doses also achieving significance versus the control gas. The two lowest doses, 0.0025 and 0.025%, had changes that were similar in magnitude and were not significantly improved versus control gas alone. PVR showed a response similar to that of PAP (p Ͻ 0.05). With the systemic parameters, there was no effect on SVR or heart rate. CO decreased after 1.25 and 2.5% ENO 2 , both when compared with the hypoxic, pre-ENO 2 state and versus control gas. Right-sided stroke work, an indirect measure of the resistance against the right ventricle, decreased with (p Ͻ 0.05 for 0.125, 1.25, and 2.5%). [There was also a decrease in stroke work (p Ͻ 0.05) when compared with the control dose for 1.25 and 2.5 ENO 2 ]. Mean arterial blood pressure rose slightly in response to the three lower doses of ENO 2 and fell slightly during administration of 1.25 and 2.5% ENO 2 . It is interesting that only the response to 0.025% reached significance (p ϭ 0.04), whereas the two highest doses showed a trend toward significance (p ϭ 0.06).
Rebound effect. We investigated the short-term effect of discontinuing ENO 2 infusion on various cardiovascular parameters, by recording for 5 min (of continued hypoxia) after the experimental period was complete. The post-ENO 2 value was statistically equivalent to the pre-ENO 2 value in each instance (data not shown).
Potentiation of ENO 2 gas in vivo. To further investigate the effects of thiol supplementation on ENO 2 , we gave glutathione (50 mg/kg) to the animals before the administration of inhaled drug. The effects of adding GSH are shown in Fig. 3 . There was a marked potentiation of the decrease in PAP and the rise in PaO 2 in response to ENO 2 ( Fig. 3A and B) ; PAP decreased by Ͼ2.5 mm Hg at the three lowest doses, whereas PaO 2 increased by 4 -5 mm Hg. With regard to PaO 2 , GSH effectively shifted the dose-effect of ENO 2 leftward, producing improvements from 0.0025 to 0.125% ENO 2 over baseline. GSH also potentiated the decrease in PVR at lower doses of ENO 2 , whereas the effect of 0.125% ENO 2 was unchanged. GSH did not seem to affect mean systemic blood pressure. An analysis of the subgroup of animals that received GSH showed no attenuation of the hypoxic vasoconstriction after GSH administration.
Measurement of methemoglobin. Methemoglobin concentrations were measured after 5 min of ENO 2 exposure ( Table  2 ). The average initial methemoglobin level was 0.7%, and there were no significant increases. The average methemoglobin after each concentration of ENO 2 was within the normal range.
Quantification of ENO 2 gas. We devised a method of measuring the amount of ENO 2 in gas phase by obtaining samples of the gas just proximal to the endotracheal tube and then analyzing it for nitrate content. Liquid concentrations of 1.25 and 2.5% gave~2000 and 4000 ppm, respectively (Fig.  4) .
DISCUSSION
Inhaled NO has been shown to reduce pulmonary pressures and improve oxygenation indices (6,25,26) in patients with pulmonary hypertension, but there is remaining concern about its toxicity in certain populations (27) (28) (29) and its use may result in methemoglobinemia (13) and platelet inhibition (30) . Inhaled alternatives to NO, including sodium nitroprusside (31, 32) , nebulized nitroglycerine (32, 33) , and various NONOates (34) have shown promise but are less well understood from the standpoint of structure-function relationships. We recently showed that the nitrosalcohol gas ENO has activity similar to that of NO but is resistant to reactions with O 2 that generate potentially toxic NO x . In further contrast with NO, ENO preferentially reacted with cysteine thiols in GSH and hemoglobin to produce SNOs that mediate its effect (18) . To better understand the structure-function relationship of these volatile drugs, we synthesized the nitrosalcohol ENO 2 . That is, we effectively oxidized the NO moiety in ENO to an NO 2 group. We report that this modification attenuates the potency of the drug. We also report, however, that the potency was restored by the addition of a thiol. Thus, we have synthesized a novel compound in our laboratory that selectively lowers PAP and raises PO 2 while also suppressing the tendency to produce methemoglobin and toxic NO x (NO/O 2 byproducts). ENO 2 's activity is further regulatable by thiols. We based our experimental protocol on our previous experience with ENO (18), a potent vasodilator gas that is synthesized in ethanol. There are, however, some notable differences between ENO and ENO 2 . Although volatile, ENO 2 is a liquid (it has a boiling point of 87.2°C). We synthesized ENO 2 using propylene glycol-an odorless, colorless, slightly viscous liquid that boils at 189°C-as a solvent. Propylene glycol has been "generally recognized as safe" by the U.S. Food and Drug Administration. Although heavy occupational exposure can lead to upper airway irritation (35) , it has been recommended as an appropriate vehicle for routine administration of bronchodilator drugs (36, 37) . It was not anticipated that our procedure, performed at room temperature, would lead to significant exposure to inhaled propylene glycol.
We compared the in vitro activities of ENO and ENO 2 in organ chamber bioassays. Although both have vasodilatory properties, ENO 2 was almost 100-fold less potent. The potency of ENO 2 in vivo was also~100 times less than that of NO and ENO. Notably, however, with the addition of GSH, the activity of ENO 2 in vivo mirrored that of ENO. Specifically, we found marked potentiation by GSH of the effects of ENO 2 on PAP, PVR, and PaO 2 (Fig. 2) . In addition, inhaled ENO 2 caused a dose-dependent decrease in right-sided stroke work (p Ͻ 0.01) and improved oxygenation, which suggests that the decrease in PVR led to improved V/Q matching. A fall in CO in these experiments is mainly attributable to a reversal of the rise in CO that accompanied induction of hypoxia. Systemically, there are minimal alterations, with a dose of 2.5% causing a drop in mean blood pressure comparable to the control gas and no difference in SVR.
The phenomenon of the rebound response is one of the major complications of stopping prolonged inhaled NO therapy (27, 38, 39) . Our protocol allowed for monitoring the response of the animal for an interval of only 5 min after stopping ENO 2 inhalation. As the rebound effect was not the major focus of this investigation, we merely noted its absence in this protocol. Similarly, we recognize that our measurement of methemoglobin formation, after only 5 min of ENO 2 exposure, may not be representative of prolonged administration. However, it is important to note that in contrast to what is seen with NO at relatively high concentrations, the high doses of ENO (2000 ppm) did not cause an increase in methemoglobin.
The biotransformation of organic nitrates involves reactions with sulfhydryl groups (thiols), which may be used in converting NO 2 groups to NO and SNOs. Once in the vascular smooth muscle cell, NO or SNO activates soluble guanylate cyclase to increase intracellular cyclic GMP (40) . This in turn leads to a decrease in intracellular calcium and relaxation of vascular smooth muscle. Previous studies have shown a potentiation of nitrate vasodilation by GSH (41, 42) , which constitutes Ͼ90% of the intracellular nonprotein thiol pool (40) . In our studies, GSH increased the efficacy of ENO 2 (as measured by changes in PAP and PaO 2 ) at the two lowest doses but not at the higher doses (0.125% or higher), concentrations at which the effect of the drug had plateaued. That is, the blood vessels were evidently maximally dilated by the highest doses of ENO 2 . In effect, pretreating animals with GSH shifted the dose-response curve to the left.
CONCLUSION
In summary, we have synthesized an organic nitrate that has not been previously studied in mammals. It relaxes constricted pulmonary artery segments in vitro and alleviates pulmonary hypertension and hypoxemia under clinically relevant conditions. Although its effective vaporized concentration is significantly higher than that recommended for NO, it does not seem after short-term administration to produce methemoglobinemia or systemic cardiovascular side effects. In addition, its activity is potentiated by the addition of thiols. This drug merits further studies for optimal dosing and long-term effects, and holds promise as a potential alternative to inhaled NO, particularly in inflammatory settings in which thiol depletion may occur.
